AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Scotiabank Analyst Says

AbbVie (NYSE:ABBV) had its price objective lifted by stock analysts at Scotiabank from $280.00 to $320.00 in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm currently has a “sector outperform” rating on the stock. Scotiabank’s price objective would indicate a potential upside of 17.92% from the company’s current price.

ABBV has been the topic of a number of other research reports. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $225.00 price objective (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Piper Sandler boosted their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. UBS Group increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Oppenheimer raised their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Finally, Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $274.32.

AbbVie Stock Performance

NYSE ABBV opened at $271.37 on Tuesday. The firm has a market capitalization of $479.44 billion, a P/E ratio of 76.66, a PEG ratio of 1.22 and a beta of 0.24. The stock has a 50-day simple moving average of $258.27 and a two-hundred day simple moving average of $235.87. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $274.94.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts forecast that AbbVie will post 13.93 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Hedge funds have recently made changes to their positions in the company. Retirement Wealth Solutions LLC boosted its stake in shares of AbbVie by 815.8% in the third quarter. Retirement Wealth Solutions LLC now owns 1,740 shares of the company’s stock worth $455,000 after acquiring an additional 1,550 shares during the last quarter. Cooper Financial Group raised its stake in AbbVie by 23.0% in the 3rd quarter. Cooper Financial Group now owns 14,096 shares of the company’s stock valued at $3,687,000 after purchasing an additional 2,636 shares during the last quarter. Elm3 Financial Group LLC purchased a new position in AbbVie in the 3rd quarter valued at $449,000. Canandaigua National Trust Co of Florida purchased a new position in AbbVie in the 3rd quarter valued at $697,000. Finally, Bath Savings Trust Co boosted its stake in AbbVie by 7.0% during the 3rd quarter. Bath Savings Trust Co now owns 24,337 shares of the company’s stock worth $6,366,000 after purchasing an additional 1,586 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review of the c-Met-directed antibody-drug conjugate, strengthening AbbVie’s oncology pipeline. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: AbbVie and Genmab reported that Epkinly (epcoritamab) plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 result met its progression-free-survival goal and could support expanded use of Epkinly, potentially increasing its commercial opportunity and competitive position against Roche’s Polivy. AbbVie Epkinly Frontline DLBCL Results
• Positive Sentiment: Scotiabank raised its AbbVie price target to $320 from $280 and maintained a “sector outperform” rating, citing the company’s growth prospects. The higher target adds to bullish analyst sentiment following the oncology updates. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may look for evidence that newer products can offset long-term pressure from Humira and support the company’s full-year outlook. AbbVie Third-Quarter Earnings Preview
• Negative Sentiment: AbbVie narrowed its third-quarter 2026 EPS guidance to $3.73–$3.77, below the $3.85 analyst consensus cited in reports. Separately, commentary highlighted a reported payout ratio above 190%, raising questions about the sustainability of the dividend if earnings or cash flow weaken. AbbVie Third-Quarter Guidance

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.